Storm Therapeutics has closed a $56 million series C financing and launched a Phase 2 trial of its lead asset for sarcoma patients.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Storm Therapeutics has closed a $56 million series C financing and launched a Phase 2 trial of its lead asset for sarcoma patients.